Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Franco Bambi is active.

Publication


Featured researches published by Franco Bambi.


Cancer Research | 2010

Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.

Giulia Grisendi; Rita Bussolari; Luigi Cafarelli; István Peták; Valeria Rasini; Elena Veronesi; Giorgio De Santis; Carlotta Spano; Mara Tagliazzucchi; Helga Barti-Juhasz; Laura Scarabelli; Franco Bambi; Antonio Frassoldati; Giulio Rossi; Christian Casali; Uliano Morandi; Edwin M. Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici

Adipose-derived mesenchymal stromal/stem cells (AD-MSC) may offer efficient tools for cell-based gene therapy approaches. In this study, we evaluated whether AD-MSC could deliver proapoptotic molecules for cancer treatment. Human AD-MSCs were isolated and transduced with a retroviral vector encoding full-length human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a proapoptotic ligand that induces apoptosis in a variety of human cancers but not normal tissues. Although several studies have documented the antitumor activity of recombinant human TRAIL, its use in vivo is limited by a short half-life in plasma due to a rapid clearance by the kidney. We found that these limitations can be overcome using stably transduced AD-MSC, which could serve as a constant source of TRAIL production. AD-MSC armed with TRAIL targeted a variety of tumor cell lines in vitro, including human cervical carcinoma, pancreatic cancer, colon cancer, and, in combination with bortezomib, TRAIL-resistant breast cancer cells. Killing activity was associated with activation of caspase-8 as expected. When injected i.v. or s.c. into mice, AD-MSC armed with TRAIL localized into tumors and mediated apoptosis without significant apparent toxicities to normal tissues. Collectively, our results provide preclinical support for a model of TRAIL-based cancer therapy relying on the use of adipose-derived mesenchymal progenitors as cellular vectors.


The Journal of Clinical Endocrinology and Metabolism | 2013

Genome-wide association study on differentiated thyroid cancer.

Aleksandra Köhler; Bowang Chen; Federica Gemignani; Rossella Elisei; Cristina Romei; Gisella Figlioli; Monica Cipollini; Alfonso Cristaudo; Franco Bambi; Per Hoffmann; Stefan Herms; Michał Kalemba; Dorota Kula; Shelley Harris; Peter Broderick; Richard S. Houlston; Susana Pastor; Ricard Marcos; Antonia Velázquez; Barbara Jarzab; Kari Hemminki; Stefano Landi; Asta Försti

CONTEXT Genome-wide association studies (GWASs) of differentiated thyroid cancer (DTC) have identified associations with polymorphisms at 2q35 (DIRC3), 8p12 (NRG1), 9q22.33 (FOXE1), and 14q13.2 (NKX2-1). However, most of the inherited genetic risk factors of DTC remain to be discovered. OBJECTIVE Our objective was to identify additional common DTC susceptibility loci. DESIGN We conducted a GWAS in a high-incidence Italian population of 690 cases and 497 controls and followed up the most significant polymorphisms in 2 additional Italian series and in 3 low-incidence populations totaling 2958 cases and 3727 controls. RESULTS After excluding the most robust previously identified locus (9q22.33), the strongest association was shown by rs6759952, confirming the recently published association in DIRC3 (odds ratio [OR] = 1.21, P = 6.4 × 10(-10), GWAS and all replications combined). Additionally, in the combined analysis of the Italian series, suggestive associations were attained with rs10238549 and rs7800391 in IMMP2L (OR = 1.27, P = 4.1 × 10(-6); and OR = 1.25, P = 5.7 × 10(-6)), rs7617304 in RARRES1 (OR = 1.25, P = 4.6 × 10(-5)) and rs10781500 in SNAPC4/CARD9 (OR = 1.23, P = 3.5 × 10(-5)). CONCLUSIONS Our findings provide additional insights into the genetic and biological basis of inherited genetic susceptibility to DTC. Additional studies are needed to determine the role of the identified polymorphisms in the development of DTC and their possible use in the clinical practice.


Cytotherapy | 2010

GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion

Giulia Grisendi; Cecilia Annerén; Luigi Cafarelli; Rita Sternieri; Elena Veronesi; Gian Luca Cervo; Stefano Luminari; Michela Maur; Antonio Frassoldati; Giovanni Palazzi; Satoru Otsuru; Franco Bambi; Paolo Paolucci; Conte Pierfranco; Edwin M. Horwitz; Massimo Dominici

BACKGROUND AIMS Bone marrow (BM) mesenchymal stromal/stem cells (MSC) are therapeutic tools in regenerative medicine and oncology. MSC isolation is often performed starting from a separation step based on research-grade 1.077 g/mL density gradient media (DGM). However, MSC clinical application should require the introduction of good manufacturing practice (GMP) reagents. We took advantage of two novel GMP DGM with densities of 1.077 and 1.073 g/mL (Ficoll-Paque PREMIUM and Ficoll-Paque PREMIUM 1.073, respectively) to test whether these reagents could isolate MSC efficiently while simultaneously comparing their performance. METHODS BM samples were processed using either 1.077 or 1.073 g/mL GMP DGM. BM mononucleated cell (MNC) fractions were analyzed for viability, immunophenotype, clonogenic potential, ex vivo expansion and differentiation potential. RESULTS No differences were noticed in cell recovery and viability between the groups. Fluorescence-activated cell-sorting (FACS) analyzes on freshly isolated cells indicated that the 1.073 g/mL GMP DGM more efficiently depleted the CD45(+) fraction in comparison with 1.077 GMP DGM. Moreover, in the 1.073 group, fibroblastic colony-forming units (CFU-F) were 1.5 times higher and the final MSC yield 1.8 times increased after four passages. Both reagents isolated MSC with the expected phenotype; however, 1.073-isolated MSC showed a higher expression of CD90, CD146 and GD2. Additionally, MSC from both groups were capable of fully differentiating into bone, adipose cells and cartilage. CONCLUSIONS Both GMP DGM enriched MSC from BM samples, suggesting that these reagents would be suitable for clinical-grade expansions. In addition, the density of 1.073 g/mL provides a significant advantage over 1.077 g/mL GMP DGM, impacting the quantity of MSC obtained and reducing the ex vivo expansion time for optimized cell-based clinical applications.


Stem Cell Research & Therapy | 2016

Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future.

Giuseppe Astori; Eliana Amati; Franco Bambi; Martina Bernardi; Katia Chieregato; Richard Schäfer; Sabrina Sella; Francesco Rodeghiero

The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing–thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl2.PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users.


Stem Cells | 2016

Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1.

Pedro Barcellos‐de‐Souza; Giuseppina Comito; Coral Pons‐Segura; Maria Letizia Taddei; Valentina Gori; Valentina Becherucci; Franco Bambi; Francesca Margheri; Anna Laurenzana; Mario Del Rosso; Paola Chiarugi

Tumor stromal cells can supply appropriate signals that may develop aggressive phenotypes of carcinoma cells and establish a complex scenario which culminates in metastasis. Recent works proposed that bone marrow‐derived mesenchymal stem cells (MSC) are recruited to primary tumors. However, the exact functions of these cells in the tumor microenvironment are not well characterized, as it is reported that MSC can either promote or inhibit tumor progression. In the present study, we aim at investigating the signaling molecules which regulate the interplay between MSC, prostate carcinoma (PCa) cells and two important cellular types constituting the tumor‐associated stroma, macrophages and fibroblasts, during their progression toward malignancy. We identified TGF‐β1 as a crucial molecule able to attract MSC recruitment both to PCa cells as well as to tumor stroma components. Moreover, PCa‐ and tumor stroma‐secreted TGF‐β1 is important to induce MSC transdifferentiation into carcinoma‐associated fibroblast (CAF)‐like cells. Consequently, the CAF‐like phenotype acquired by MSC is central to promote tumor progression related effects. Thus, tumor‐educated MSC enhance PCa invasiveness compared to nonactivated MSC. Additionally, differing from normal MSC, CAF‐like MSC perform vascular mimicry and recruit monocytes, which can be further polarized to M2 macrophages within the PCa environment. Our findings indicate a prominent role for TGF‐β1 in MSC mobilization and activation strengthened by the fact that the blockade of TGF‐β1 signaling impairs MSC promotion of PCa progression. Stem Cells 2016;34:2536–2547


The Journal of Clinical Endocrinology and Metabolism | 2014

Novel Genome-Wide Association Study-Based Candidate Loci for Differentiated Thyroid Cancer Risk

Gisella Figlioli; Aleksandra Köhler; Bowang Chen; Rossella Elisei; Cristina Romei; Monica Cipollini; Alfonso Cristaudo; Franco Bambi; Elisa Paolicchi; Per Hoffmann; Stefan Herms; Michał Kalemba; Dorota Kula; Susana Pastor; Ricard Marcos; Antonia Velázquez; Barbara Jarząb; Stefano Landi; Kari Hemminki; Asta Försti; Federica Gemignani

CONTEXT Genome-wide association studies (GWASs) on differentiated thyroid cancer (DTC) have identified robust associations with single nucleotide polymorphisms (SNPs) at 9q22.33 (FOXE1), 14q13.3 (NKX2-1), and 2q35 (DIRC3). Our recently published GWAS suggested additional susceptibility loci specific for the high-incidence Italian population. OBJECTIVE The purpose of this study was to identify novel Italian-specific DTC risk variants based on our GWAS and to test them further in low-incidence populations. DESIGN We investigated 45 SNPs selected from our GWAS first in an Italian population. SNPs that showed suggestive evidence of association were investigated in the Polish and Spanish cohorts. RESULTS The combined analysis of the GWAS and the Italian replication study (2260 case patients and 2218 control subjects) provided strong evidence of association with rs10136427 near BATF (odds ratio [OR] =1.40, P = 4.35 × 10(-7)) and rs7267944 near DHX35 (OR = 1.39, P = 2.13 × 10(-8)). A possible role in DTC susceptibility in the Italian populations was also found for rs13184587 (ARSB) (P = 8.54 × 10(-6)) and rs1220597 (SPATA13) (P = 3.25 × 10(-6)). Only the associations between rs10136427 and rs7267944 and DTC risk were replicated in the Polish and the Spanish populations with little evidence of population heterogeneity (GWAS and all replications combined, OR = 1.30, P = 9.30 × 10(-7) and OR = 1.32, P = 1.34 × 10(-8), respectively). In silico analyses provided new insights into the possible functional consequences of the SNPs that showed the strongest association with DTC. CONCLUSIONS Our findings provide evidence for novel DTC susceptibility variants. Further studies are warranted to identify the specific genetic variants responsible for the observed associations and to functionally validate our in silico predictions.


Digestive and Liver Disease | 2013

Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium

Daniele Campa; Cosmeri Rizzato; Gabriele Capurso; Nathalia A. Giese; Niccola Funel; William Greenhalf; Pavel Soucek; Maria Gazouli; Raffaele Pezzilli; Claudio Pasquali; Renata Talar-Wojnarowska; Maurizio Cantore; Angelo Andriulli; Aldo Scarpa; Krzysztof Jamroziak; Gianfranco Delle Fave; Eithne Costello; Kay-Tee Khaw; Anette Heller; Timothy J. Key; George Theodoropoulos; Ewa Małecka-Panas; Andrea Mambrini; Franco Bambi; Stefano Landi; Sergio Pedrazzoli; Claudio Bassi; Paola Pacetti; Ada Piepoli; Francesca Tavano

Pancreatic cancer is the fourth leading cause of cancer deaths in the European Union and in the USA, but little is known about its genetic susceptibility. The PANcreatic Disease ReseArch (PANDoRA) consortium was established to unite the efforts of different research groups; its aim is to create a large bio-database to uncover new genetic factors for pancreatic cancer risk, response to treatment, and patient survival. So far 2220 cases of pancreatic adenocarcinoma, a smaller number of cases of endocrine pancreatic tumours (n=86), chronic pancreatitis (n=272) and 3847 healthy controls have been collected. As a collective effort of the consortium, SNPs associated with pancreatic adenocarcinoma risk from a genome-wide association study performed in Caucasians were replicated. The possibility that the same genetic polymorphisms may influence patient survival as well was also addressed. This collective effort is particularly important for pancreatic cancer because it is a relatively rare disease for which little is known about aetiopathogenesis and risk factors. The recruitment of additional collaborators and partner institutions is continuously on-going.


Stem Cells | 2015

Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis

Olivia Candini; Carlotta Spano; Alba Murgia; Giulia Grisendi; Elena Veronesi; Maria Serena Piccinno; Manuela Ferracin; Massimo Negrini; Francesca Giacobbi; Franco Bambi; Edwin M. Horwitz; Pierfranco Conte; Paolo Paolucci; Massimo Dominici

Human aging is associated with a decrease in tissue functions combined with a decline in stem cells frequency and activity followed by a loss of regenerative capacity. The molecular mechanisms behind this senescence remain largely obscure, precluding targeted approaches to counteract aging. Focusing on mesenchymal stromal/stem cells (MSC) as known adult progenitors, we identified a specific switch in miRNA expression during aging, revealing a miR‐196a upregulation which was inversely correlated with MSC proliferation through HOXB7 targeting. A forced HOXB7 expression was associated with an improved cell growth, a reduction of senescence, and an improved osteogenesis linked to a dramatic increase of autocrine basic fibroblast growth factor secretion. These findings, along with the progressive decrease of HOXB7 levels observed during skeletal aging in mice, indicate HOXB7 as a master factor driving progenitors behavior lifetime, providing a better understanding of bone senescence and leading to an optimization of MSC performance. Stem Cells 2015;33:939–950


International Journal of Cancer | 2015

TERT gene harbors multiple variants associated with pancreatic cancer susceptibility

Daniele Campa; Cosmeri Rizzato; Rachael S. Stolzenberg-Solomon; Paola Pacetti; Pavel Vodicka; Sean P. Cleary; Gabriele Capurso; H. B. Bueno-De-Mesquita; Jens Werner; Maria Gazouli; Katja Butterbach; Audrius Ivanauskas; Nathalia A. Giese; Gloria M. Petersen; Paola Fogar; Zhaoming Wang; Claudio Bassi; Miroslav Ryska; George Theodoropoulos; Charles Kooperberg; Donghui Li; William Greenhalf; Claudio Pasquali; Thilo Hackert; Charles S. Fuchs; Beatrice Mohelnikova-Duchonova; Cosimo Sperti; Niccola Funel; Aida Karina Dieffenbach; Nicholas J. Wareham

A small number of common susceptibility loci have been identified for pancreatic cancer, one of which is marked by rs401681 in the TERT–CLPTM1L gene region on chromosome 5p15.33. Because this region is characterized by low linkage disequilibrium, we sought to identify whether additional single nucleotide polymorphisms (SNPs) could be related to pancreatic cancer risk, independently of rs401681. We performed an in‐depth analysis of genetic variability of the telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC) genes, in 5,550 subjects with pancreatic cancer and 7,585 controls from the PANcreatic Disease ReseArch (PANDoRA) and the PanScan consortia. We identified a significant association between a variant in TERT and pancreatic cancer risk (rs2853677, odds ratio = 0.85; 95% confidence interval = 0.80–0.90, p = 8.3 × 10−8). Additional analysis adjusting rs2853677 for rs401681 indicated that the two SNPs are independently associated with pancreatic cancer risk, as suggested by the low linkage disequilibrium between them (r2 = 0.07, D′ = 0.28). Three additional SNPs in TERT reached statistical significance after correction for multiple testing: rs2736100 (p = 3.0 × 10−5), rs4583925 (p = 4.0 × 10−5) and rs2735948 (p = 5.0 × 10−5). In conclusion, we confirmed that the TERT locus is associated with pancreatic cancer risk, possibly through several independent variants.


Cancer Epidemiology, Biomarkers & Prevention | 2013

Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations

Daniele Campa; Cosmeri Rizzato; Andrea Bauer; Jens Werner; Gabriele Capurso; Eithne Costello; Renata Talar-Wojnarowska; Krzysztof Jamroziak; Raffaele Pezzilli; Maria Gazouli; Kay-Tee Khaw; Timothy J. Key; Franco Bambi; Beatrice Mohelnikova-Duchonova; Anette Heller; Stefano Landi; Ludmila Vodickova; George Theodoropoulos; Peter Bugert; Pavel Vodicka; Jörg D. Hoheisel; Gianfranco Delle Fave; John P. Neoptolemos; Pavel Soucek; Markus W. Büchler; Nathalia A. Giese; Federico Canzian

Background: Two recent genome-wide association studies (GWAS) of pancreatic ductal adenocarcinoma (PDAC), conducted, respectively, in a Japanese and in a Chinese population, identified eight novel loci affecting PDAC risk. Methods: We attempted to replicate the novel loci in a series of PDACs and healthy controls of European ancestry in the context of the newly formed PANcreatic Disease ReseArch (PANDoRA) consortium. We genotyped seven single-nucleotide polymorphisms (SNP): rs12413624, rs1547374, rs372883, rs5768709, rs6464375, rs708224, rs9502893 (one SNP identified in the Chinese GWAS is not polymorphic in Caucasians) in 1,299 PDAC cases and 2,884 controls. We also attempted stratified analysis considering the different stages of the disease and addressed the possible involvement of the selected SNPs on the survival of patients. Results: None of the SNPs were significantly associated with PDAC risk if considering the overall population of the consortium. When stratifying for country of origin, we found that in the Polish subgroup, the G allele of rs372883 was statistically significantly associated with increased risk [OR, 6.40; 95% confidence interval (CI), 2.28–17.91]. However, the sample size of the subgroups was rather small; therefore, this result can be due to chance. None of the SNPs was associated with disease progression or survival. Conclusions: None of the SNPs associated with PDAC risk in two Asian populations were convincingly associated with PDAC risk in individuals of European descent. Impact: This study illustrates the importance of evaluation of PDAC risk markers across ethnic groups. Cancer Epidemiol Biomarkers Prev; 22(2); 320–3. ©2012 AACR.

Collaboration


Dive into the Franco Bambi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gabriele Capurso

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge